PEOPLE - Affibody makes appointment:
This article was originally published in Clinica
Stockholm-based Swedish biotech firm Affibody has promoted Ulf Boberg to CEO. Dr Boberg, who joined the firm in January 2006 as senior vice-president for development, replaces acting CEO Dr Carl-Johan Dalsgaard, who will remain a non-executive board member. Dr Boberg's 18 years' experience in the industry include several leading and financial roles, most recently as CEO of Global Genomics AB. Other positions include: senior VP and head of the development division of Astra Pain Control; investment manager of LinkMed AB; and head of Medical Research at Gambro.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.